Nov. 26, 2012
/PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced that it will host a conference call to discuss the broadened Intermezzo® commercialization strategy and consumer advertising campaign by Purdue Pharmaceutical Products, L.P.
Conference Call Information
Tuesday, November 27, 2012
8:30 a.m. ET
Dial-in (U.S.): 877-638-4558Dial-in (International): 914-495-8537
A simultaneous web cast of the conference call will be available on the Investors section of the Transcept website at
. A replay of the call will be available on the website shortly after the conclusion of the call until
January 30, 2013
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in
the United States
. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit
. For information about Intermezzo, please visit
Transcept Pharmaceuticals, Inc.
Sr. Director, Corporate Communications(510) 215-3567
SOURCE Transcept Pharmaceuticals, Inc.